Dala Care

Accelerating Breakthroughs For Age-Related Medical Conditions

About this Event

Every day, 10,000 Americans turn 65, yet the fastest-growing patient population remains largely invisible to medical research because they are so hard to recruit for clinical trials. The result is a massive gap in drug development and billions lost to delayed trials.

Dala Care is solving this problem by building “Flatiron Health” for the aging-in-place population. It is a unified platform connecting home care agencies, families, and life sciences companies.

Their AI-driven operating system helps home care agencies manage scheduling, care plans, and communication while generating real-world clinical data from caregiver visits. That data powers a research marketplace enabling pharmaceutical companies to identify and recruit older adults who have opted-in for communications, something that is currently impossible to do at scale.

The impact is profound: accelerating medical breakthroughs for Alzheimer’s, cardiovascular disease, and other age-related conditions, while improving care for millions of seniors.

Dala Care provides its platform to home care agencies at cost and earns small percentage on billables. On the life sciences side, pharmaceutical companies and clinical research organizations pay for platform access, qualified patient referrals, and successful trial enrollments.

Register today to watch our online event with Dala Care CEO, Finnur Magnusson. The company already has $1.2M ARR, a rapidly expanding patient network, partnerships with major care providers, and contracts with leading research organizations for 48 trials.

Video On Demand

– Recorded

April 2

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.